Filing Flows › Champions Oncology (CSBR) › Q4 FY26
Champions Oncology (CSBR) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jul 27, 2026
Champions Oncology (CSBR) reported revenue of $13.8M for the fourth quarter fiscal 2026 (Q4 FY26), +12% from a year earlier and -16% from the quarter before. Operating margin was -3.8%, net loss $667K (4.8% of revenue).
Champions Oncology, Q4 FY26: revenue $13.8M (+12% year over year), operating margin -3.8%, net loss $667K, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | -16% | +12% |
| Operating profit | −$522K | — | — |
| Net earnings | −$667K | — | — |
| Operating cash flow | −$2.0M | — | -129% |
What changed
Revenue was $13.8M in Q4 FY26, up 12% year over year and down 16% from the previous quarter. Pharmacology services was the largest line at 95% of revenue.
Operating costs exceeded revenue by $522K, an operating margin of -3.8%. Total costs fell 0% while revenue rose 12%. The fastest-growing cost line was Sales & marketing (+21%). The quarter ended with a net loss of $667K, wider than the previous quarter's $278K loss.
Operating cash flow was −$2.0M. Non-cash charges added back $300K of depreciation and amortization and $357K of share-based compensation. Working capital and other items used $2.0M. Capital expenditures of $239K exceeded it, leaving free cash flow of −$2.2M.
Questions
What was Champions Oncology's revenue in the fourth quarter fiscal 2026?
Champions Oncology (CSBR) reported revenue of $13.8M for the fourth quarter fiscal 2026 (Q4 FY26), +12% from a year earlier and -16% from the quarter before.
Was Champions Oncology profitable in the fourth quarter fiscal 2026?
Operating loss was $522K (-3.8% of revenue) and net loss $667K.
Source: Champions Oncology 10-K on SEC EDGAR.